- Home
- HEPA vs ISPC Comparison
HEPA vs ISPC Comparison
Compare HEPA & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- ISPC
- Stock Information
- Founded
- HEPA 2013
- ISPC 2009
- Country
- HEPA United States
- ISPC United States
- Employees
- HEPA N/A
- ISPC N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- HEPA Health Care
- ISPC Health Care
- Exchange
- HEPA Nasdaq
- ISPC Nasdaq
- Market Cap
- HEPA 4.1M
- ISPC 4.7M
- IPO Year
- HEPA N/A
- ISPC 2021
- Fundamental
- Price
- HEPA $0.57
- ISPC $3.86
- Analyst Decision
- HEPA Hold
- ISPC
- Analyst Count
- HEPA 1
- ISPC 0
- Target Price
- HEPA N/A
- ISPC N/A
- AVG Volume (30 Days)
- HEPA 27.9K
- ISPC 222.6K
- Earning Date
- HEPA 11-14-2024
- ISPC 11-07-2024
- Dividend Yield
- HEPA N/A
- ISPC N/A
- EPS Growth
- HEPA N/A
- ISPC N/A
- EPS
- HEPA N/A
- ISPC N/A
- Revenue
- HEPA N/A
- ISPC $10,390,702.00
- Revenue This Year
- HEPA N/A
- ISPC $13.82
- Revenue Next Year
- HEPA N/A
- ISPC $11.76
- P/E Ratio
- HEPA N/A
- ISPC N/A
- Revenue Growth
- HEPA N/A
- ISPC 0.74
- 52 Week Low
- HEPA $0.48
- ISPC $2.76
- 52 Week High
- HEPA $3.72
- ISPC $12.20
- Technical
- Relative Strength Index (RSI)
- HEPA 39.66
- ISPC 35.78
- Support Level
- HEPA $0.48
- ISPC $2.76
- Resistance Level
- HEPA $0.66
- ISPC $4.66
- Average True Range (ATR)
- HEPA 0.06
- ISPC 0.40
- MACD
- HEPA -0.01
- ISPC -0.07
- Stochastic Oscillator
- HEPA 32.88
- ISPC 23.16
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.